Alloy Therapeutics, Inc.’s Post

On Monday, March 11, Caribou Biosciences released its Q4 and FY 2023 results (press release: https://bit.ly/3PkfkXP) highlighting that an updated timeline for the initiation of CB-010’s (allogeneic #CD19 CAR-T) pivotal Ph3 trial in ≥2L #LBCL is expected in Q2 2024 while noting that the first patient has been dosed in the Ph1 #AMpLify trial (https://bit.ly/49WSjCv) evaluating CB-012 (allogeneic CLL-1 CAR-T) in ≥4L #MM. Of note, the company has paused the development of CB-020 (allogeneic ROR-1 CAR-iNK) as part of a regular portfolio prioritization process. Celltelligence provides insights on the lack of guidance for the estimated initiation date of CB-010’s pivotal Ph3 trial while commenting on Caribou’s overall strategy for advancing its clinical #celltherapy assets: https://bit.ly/CT-861772

Washington University launches translational DiviTum® TKa trial: BettER! This study seeks to evaluate the impact of early therapeutic switching based on biomarker-driven insights, utilizing DiviTum TKa to guide treatment decisions. Read the full Press release: https://loom.ly/ay43Vvg "We are thrilled to once again collaborate with Washington University on another trial. This time it is a translational trial, which if successful would pave the way for increased uptake of DiviTum TKa, for the benefit of patients," said Anders Rylander, CEO of Biovica. #PrecisionMedicine #clinicaltrials #biomarkers #bcsm #investors #biovicb

Drug Delivery to the Lungs Conference (DDL) in Edinburgh is approaching and our team could not be more enthusiastic! Patrícia Henriques is one of the finalists of The Pat Burnell Young Investigator Award and will present the paper “In vitro-In vivo Correlations (IVIVC) of Amorphous Solid Dispersions for Nasal Delivery” showing why IVIVC is a valuable tool to support the use of “in vitro” performance methodologies as well as to guide formulation and process development. In her presentation she will navigate through recent results that show that amorphous solid dispersions (ASD) of poorly soluble drugs for nasal delivery obtained by spray drying are able to improve drug release and permeation, ultimately resulting in faster drug absorption. Want to learn more? Connect with our experts at DDL - Booth No.168. Schedule a meeting today: https://lnkd.in/de2Q_eFr Hovione – Delivering Solutions every breath of the way #DDL2024 #inhalation #nasal #DPI #inhaler #respiratory #drugproduct #drugdelivery #drugdevelopment #formulation #analytical #cdmo #initforlife

Sarcoidosis Awareness Month! 🗓 As we delve deeper into the Month of Sarcoidosis Awareness, last week marked a pivotal moment for our ongoing efforts in combating #PulmonarySarcoidosis. ODC orchestrated a dynamic Investigator Meeting in collaboration with aTyr Pharma, focusing on our groundbreaking trial currently underway in Brazil, aimed at recruiting patients for this critical cause. The trial sites' collective expertise and commitment generated insightful discussions delving into the trial itself and the intricacies of Pulmonary Sarcoidosis. Together, we are not only advancing science but also reshaping lives! #PulmonarySarcoidosisAwareness #ClinicalResearch #MedicalInnovation

So what's the common thread between successful biotech CEOs ? In preparing for this panel I thought doing 1-1 calls ahead of time would be a cool way to get to know a set of accomplished CEOs from the New England biotech community. The odds of getting everyone on one Teams call seemed pretty low right ? Well, let me say these calls have been an absolute highlight of the past month for me. The most important takeaway observation (if you can't make it to COG New England next week): The passion these CEOs have for the underlying patient challenges is what gets them moving each day. The fundraising and clinical data journey isn't easy. These CEOs press forward through that difficult journey because they understand they have an opportunity to help bring cures and treatments to the people that need them.

The #STORM team is pleased to share that it will be presenting a poster at the upcoming EORTC-NCI-AACR (#ENA) Symposium, being held in Barcelona, Spain from 23-25 October!   The poster, titled 'First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies’, will highlight updated interim results from STORM's Phase 1 trial with its first-in-class lead product, STC-15.   STC-15 is a potent and selective oral small molecule that inhibits METTL3 and is the first molecule specifically targeting an RNA methyltransferase enzyme in clinical development.   💡 Find out more about STORM's Phase 1 trial and its upcoming poster details in the press release linked in the comments below!   #lifesciences #biotech #drugdiscovery #research #STC15 #METTL3 #METTL1 #RNA #ENA

This week, we're at the TD Cowen 44th Annual Health Care Conference. We kicked off the morning with Nathan Dowden, President and Chief Operating Officer, who joined Joseph Thome, PhD, Managing Director, Senior Biotechnology Equity Research Analyst at TD Cowen, on the Orphan Bone & Neuromuscular Diseases panel. Nate highlighted our pipeline of intracellular therapeutics and the important progress we have made across our neuromuscular therapeutic areas.    Here are just a few of our 2024 highlights: · Cash runway: through the second quarter 2026 · ENTR-601-44 (DMD exon 44): readout of our Phase 1 healthy normal volunteer data in the second half of 2024 · ENTR-601-45 (DMD exon 45): regulatory filing to initiate a multiple ascending dose trial in the fourth quarter 2024 · VX-670 (partnered DM1 program with Vertex): ongoing Phase 1/2 multiple ascending dose trial in DM1 patients   If you missed the panel, the replay is available here: https://lnkd.in/e6_UBk-n. Our Corporate Presentation is also available here: https://lnkd.in/e4eBUv5i   #InvestorRelations #Biotech

Day #13 of TGen's Top 20: Nicholas Schork's bold proposal for faster, personalized drug development 🌟 TGen’s Nicholas Schork is pushing the boundaries of personalized medicine with a proposal to the FDA on aggregated "n-of-1" clinical trials. By combining single-patient data, this approach could speed up drug development and create treatments tailored to each individual’s unique biology. Schork’s vision could revolutionize clinical trials, accelerating progress in rare disease therapies and beyond. 🧬💡 To learn more: https://bit.ly/3VnGmkc #Science #Research #PrecisionMedicine #Impact #Technology #Innovation #Hope #Arizona #foryoupage #fyp